Advicenne Announces the Approval of All Resolutions Supported by the Board of Directors at Its Combined General Meeting
May 15 2024 - 3:02AM
Business Wire
Regulatory News:
The Combined General Meeting of shareholders of Advicenne
(Euronext Growth Paris ALDVI - FR0013296746) (Paris:ALDVI), a
specialty pharmaceutical company dedicated to the development and
commercialization of innovative treatments for those suffering from
rare renal diseases, met on May 14, 2024, at 10 a.m. at 262, rue du
Faubourg Saint-Honoré - 75008 Paris - France.
The Combined General Meeting adopted all the resolutions put to
the vote concerning the approval of the statutory financial
statements, the granting to the Board of Directors of financial
delegations and of the delegation allowing the allocation of share
warrants, with the exception of the 16th resolution which was
rejected, in accordance with the recommendations of the Board of
Directors. The results of the vote by resolution are available on
the Company's website in the Investors section
(https://advicenne.com/investors/).
ABOUT ADVICENNE
Advicenne (Euronext: ALDVI) is a specialty pharmaceutical
company founded in 2007, specializing in the development of
innovative treatments in Nephrology. Its lead product Sibnayal® has
received Marketing Approval for distal renal tubular acidosis
(dRTA) in EU and GB. ADV7103 is currently in late-stage development
in cystinuria in Europe and in dRTA and cystinuria in the US and
Canada. Headquartered in Paris, Advicenne, listed on the Euronext
Paris stock exchange since 2017, has now been listed on Euronext
Growth Paris since its transfer on March 30, 2022. For
additional information, see: https://advicenne.com/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240515571924/en/
Advicenne Didier Laurens, CEO +33 (0) 1 87 44 40 17
Email: investors@advicenne.com
Ulysses Communication Media relations Bruno Arabian +33
(0)6 87 88 47 26 Email: advicenne@ulysse-communication.com